CFM
TSHA icon

Capricorn Fund Managers’s Taysha Gene Therapies TSHA Stock Holding History

Capricorn Fund Managers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300,000
Closed -$1.65M – 145
2025
Q4 		$1.65M Buy
+300,000
New +$1.46M 0.4% 61

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capricorn Fund Managers's TSHA Position: Q1 2026 in Review

Capricorn Fund Managers sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 300,000 shares — an estimated $1.65M sold.

Capricorn Fund Managers first reported a position in TSHA in Q4 2025 and held it in 1 quarter. The position peaked at $1.65M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Capricorn Fund Managers reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Capricorn Fund Managers sold 300,000 Taysha Gene Therapies shares in Q1 2026, an estimated $1.65M.
  • Capricorn Fund Managers first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 1 quarter.
  • Capricorn Fund Managers's Taysha Gene Therapies position peaked at $1.65M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Capricorn Fund Managers's 13F filing for Q1 2026, filed 24 Apr 2026.